

Christine Marosi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7483215/publications.pdf>

Version: 2024-02-01

190
papers

35,943
citations

36303

51
h-index

3830

178
g-index

225
all docs

225
docs citations

225
times ranked

31863
citing authors

#	ARTICLE	IF	CITATIONS
1	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
2	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	4.1	27
3	The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
4	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients. <i>Acta Neuropathologica Communications</i> , 2022, 10, 39.	5.2	6
5	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 1579.	3.7	6
6	MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. <i>Cancers</i> , 2022, 14, 2563.	3.7	7
7	Geriatric oncology: questions, answers and guidelines. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 24-28.	0.5	1
8	Elderly patients with cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 1-2.	0.5	0
9	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	4.2	10
10	Will mastering ferroptosis allow treating refractory meningiomas?. <i>Neuro-Oncology</i> , 2021, 23, 1989-1990.	1.2	1
11	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. <i>Neuro-Oncology</i> , 2021, 23, vi130-vi130.	1.2	0
12	Cancer rehabilitation: current trends and practices within an Austrian University Hospital Center. <i>Disability and Rehabilitation</i> , 2020, 42, 2-7.	1.8	23
13	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. <i>Translational Research</i> , 2020, 215, 41-56.	5.0	7
14	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. <i>Oncologist</i> , 2020, 25, e1930-e1955.	3.7	20
15	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. <i>Cancer</i> , 2020, 126, 4341-4352.	4.1	27
16	Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. <i>Current Oncology Reports</i> , 2020, 22, 93.	4.0	6
17	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	4.5	17
18	Distributed changes of the functional connectome in patients with glioblastoma. <i>Scientific Reports</i> , 2020, 10, 18312.	3.3	19

#	ARTICLE	IF	CITATIONS
19	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612.	1.6	19
20	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198.	2.9	25
21	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	2.8	10
22	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. <i>Npj Vaccines</i> , 2020, 5, 5.	6.0	19
23	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647.	4.5	4
24	Ausgangslage für Rehabilitationsmaßnahmen bei HirntumorpatientInnen. , 2020, , 227-236.		0
25	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.	4.5	4
26	GDF15 in solid vs non-solid treatment-naïve malignancies. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13168.	3.4	10
27	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
28	Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1335-1344.	3.8	25
29	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. <i>Acta Oncologica</i> , 2019, 58, 967-976.	1.8	8
30	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , 2019, 186, 311-320.	2.5	82
31	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
32	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. <i>Cancers</i> , 2019, 11, 2020.	3.7	13
33	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. <i>Radiotherapy and Oncology</i> , 2019, 130, 139-148.	0.6	11
34	Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?. <i>EBioMedicine</i> , 2018, 29, 9-10.	6.1	0
35	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615.	7.7	76
36	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.8	2

#	ARTICLE	IF	CITATIONS
37	MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi155-vi155.	1.2	0
38	Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovables. <i>Acta Neuropathologica Communications</i> , 2018, 6, 135.	5.2	37
39	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1875-1884.	3.4	38
40	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	3.7	67
41	How should adult patients with neurofibromatosis 1 be managed?. <i>Neuro-Oncology</i> , 2018, 20, 721-722.	1.2	2
42	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2396-2403.	6.4	25
43	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	30.7	229
44	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. <i>European Radiology</i> , 2017, 27, 1556-1567.	4.5	26
45	Advances in brain tumour classification and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 71-72.	10.1	13
46	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. <i>Blood</i> , 2017, 129, 1831-1839.	1.4	164
47	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017, 19, 162-174.	1.2	381
48	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	10.7	816
49	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	1.2	213
50	Milestones of the last 10 years. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.5	8
51	MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. <i>Pituitary</i> , 2017, 20, 643-653.	2.9	24
52	Rindopimut with temozolomide for patients with newly diagnosed, EGFRVIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
53	Evidence-based management of adult patients with diffuse glioma – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431.	10.7	5
54	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	4.5	4

#	ARTICLE	IF	CITATIONS
55	Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment. <i>Neuro-Oncology</i> , 2017, 19, 1280-1282.	1.2	3
56	The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. <i>Radiotherapy and Oncology</i> , 2017, 125, 228-233.	0.6	26
57	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology</i> , The, 2017, 18, e330-e340.	10.7	195
58	Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. <i>Oncotarget</i> , 2017, 8, 81250-81260.	1.8	15
59	Challenge of cancer in the elderly. <i>ESMO Open</i> , 2016, 1, e000020.	4.5	107
60	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	7.0	105
61	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532.	10.7	396
62	Gamma Knife Radiosurgery in Recurrent Glioblastoma. <i>Stereotactic and Functional Neurosurgery</i> , 2016, 94, 265-272.	1.5	27
63	Cancer rehabilitation in Austria— aspects of Physical Medicine and Rehabilitation. <i>Wiener Medizinische Wochenschrift</i> , 2016, 166, 39-43.	1.1	19
64	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma— results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	1.2	187
65	Association of platelet activation markers with cancer-associated venous thromboembolism. <i>Platelets</i> , 2016, 27, 80-85.	2.3	42
66	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	1.2	53
67	NTCT-09IGF-1 IS NOT ELEVATED IN PATIENTS WITH HGG TREATED WITH RADIOCHEMOTHERAPY. <i>Neuro-Oncology</i> , 2015, 17, v174.1-v174.	1.2	0
68	Neuropathies associated with lymphoma— . <i>Neuro-Oncology Practice</i> , 2015, 2, 167-178.	1.6	16
69	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	3.0	24
70	Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma. <i>Neuro-Oncology</i> , 2015, 17, 7-8.	1.2	3
71	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. <i>Genome Biology</i> , 2015, 16, 16.	8.8	82
72	Is dosing in oncology gender-sensitive?. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 5-10.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. <i>Journal of Neurology</i> , 2015, 262, 179-186.	3.6	20
74	Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients – A pragmatic randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2015, 23, 309-317.	2.7	78
75	Antiangiogenic Treatment of Meningiomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 359.	1.8	5
76	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	7.0	264
77	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. <i>Heart</i> , 2015, 101, 1874-1880.	2.9	181
78	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	1.2	485
79	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	2.5	64
80	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 1645-1651.	1.2	63
81	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). <i>Neuro-Oncology</i> , 2014, 16, 92-102.	1.2	57
82	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2014, 111, 670-678.	3.4	88
83	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. <i>SpringerPlus</i> , 2014, 3, 111.	1.2	21
84	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. <i>Anti-Cancer Drugs</i> , 2014, 25, 723-728.	1.4	10
85	Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna. <i>Complementary Therapies in Medicine</i> , 2014, 22, 320-332.	2.7	24
86	Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions. <i>Journal of Neuro-Oncology</i> , 2014, 116, 207-212.	2.9	13
87	The end-of-life phase of high-grade glioma patients: a systematic review. <i>Supportive Care in Cancer</i> , 2014, 22, 847-857.	2.2	68
88	The Association of Early Cognition Assessments and Progression-free Survival in Patients with Glioblastoma Multiforme. <i>The Journal of Oncopathology</i> , 2014, 1, 1-9.	0.1	2
89	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>Blood</i> , 2014, 124, 2859-2859.	1.4	3
90	PD1 and PD-L1 expression in glioblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2011-2011.	1.6	4

#	ARTICLE	IF	CITATIONS
91	A randomized clinical trial for the treatment of glioblastoma multiforme with the individualized dendritic cell-based cancer immunotherapy AV0113.. Journal of Clinical Oncology, 2014, 32, 2052-2052.	1.6	1
92	Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 76-77.	0.6	15
93	Molecular biology of high-grade gliomas: what should the clinician know?. Chinese Journal of Cancer, 2014, 33, 4-7.	4.9	24
94	QOL and neurocognitive functions in patients with GBM.. Journal of Clinical Oncology, 2014, 32, 2062-2062.	1.6	0
95	High plasma-GFAP levels in metastatic myxopapillary ependymoma. Journal of Neuro-Oncology, 2013, 113, 359-363.	2.9	8
96	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	2.9	14
97	The caregivers' perspective on the end-of-life phase of glioblastoma patients. Journal of Neuro-Oncology, 2013, 112, 403-411.	2.9	72
98	Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. Wiener Klinische Wochenschrift, 2013, 125, 481-486.	1.9	24
99	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	2.4	48
100	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thrombosis Research, 2013, 131, 162-165.	1.7	53
101	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	3.3	66
102	First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?. CNS Oncology, 2013, 2, 473-474.	3.0	1
103	Conference Scene: Neuro-oncology insights from European Society of Medical Oncology 2012. CNS Oncology, 2013, 2, 29-31.	3.0	0
104	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro-Oncology, 2013, 15, 112-121.	1.2	31
105	Frequent overexpression of ErbB receptor family members in brain metastases of non-small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	2.0	15
106	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4, 502-530.	1.8	152
107	Case Report: Pregnancy in a patient with recurrent glioblastoma. F1000Research, 2013, 2, 246.	1.6	10
108	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	2.5	38

#	ARTICLE	IF	CITATIONS
109	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. PLoS ONE, 2013, 8, e76988.	2.5	138
110	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. Journal of Clinical Oncology, 2013, 31, TPS2103-TPS2103.	1.6	0
111	Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. Anticancer Research, 2013, 33, 1065-71.	1.1	15
112	Complications of chemotherapy in neuro-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 873-885.	1.8	9
113	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 916-926.	10.7	1,075
114	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. Cancer Investigation, 2012, 30, 625-629.	1.3	19
115	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. Journal of Neuro-Oncology, 2012, 109, 323-330.	2.9	20
116	Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. Journal of Neuro-Oncology, 2012, 109, 331-339.	2.9	43
117	Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. Journal of Neuro-Oncology, 2012, 110, 221-226.	2.9	24
118	Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. Translational Oncology, 2012, 5, 56-IN4.	3.7	71
119	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	1.3	60
120	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 2012, 124, 547-560.	7.7	274
121	Drug therapy for recurrent, progressive, atypical, and malignant meningiomas. Memo - Magazine of European Medical Oncology, 2012, 5, 218-222.	0.5	0
122	News from the Neuro-Oncology front. Memo - Magazine of European Medical Oncology, 2012, 5, 169-170.	0.5	0
123	The End-of-Life in patients with glioma and their families. Memo - Magazine of European Medical Oncology, 2012, 5, 233-235.	0.5	0
124	Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer, 2012, 118, 5038-5049.	4.1	57
125	Temozolomide Dosing Regimens for Glioma Patients. Current Neurology and Neuroscience Reports, 2012, 12, 286-293.	4.2	34
126	Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients. Wiener Klinische Wochenschrift, 2012, 124, 377-383.	1.9	18

#	ARTICLE	IF	CITATIONS
127	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. <i>Neurosurgical Review</i> , 2012, 35, 381-391.	2.4	86
128	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. <i>Magnetic Resonance Imaging</i> , 2012, 30, 139-147.	1.8	39
129	Pilot study on sex hormone levels and fertility in women with malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 387-394.	2.9	10
130	Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna. <i>Wiener Medizinische Wochenschrift</i> , 2012, 162, 18-28.	1.1	3
131	Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. <i>Supportive Care in Cancer</i> , 2012, 20, 175-183.	2.2	39
132	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	7.7	163
133	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2053-2053.	1.6	0
134	Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS).. <i>Blood</i> , 2012, 120, 2253-2253.	1.4	0
135	Clinical fMRI: Evidence for a 7T benefit over 3T. <i>NeuroImage</i> , 2011, 57, 1015-1021.	4.2	110
136	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	1.8	38
137	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. <i>European Journal of Clinical Investigation</i> , 2011, 41, 539-545.	3.4	2
138	Editorial: Behandlung von Glioblastomrezidiven. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 1-2.	1.1	3
139	Myxopapillary Ependymoma With Pleuropulmonary Metastases and High Plasma Glial Fibrillary Acidic Protein Levels. <i>Journal of Clinical Oncology</i> , 2011, 29, e756-e757.	1.6	14
140	Prediction of venous thromboembolism in cancer patients. <i>Blood</i> , 2010, 116, 5377-5382.	1.4	643
141	Neurocognitive training in patients with high-grade glioma: a pilot study. <i>Journal of Neuro-Oncology</i> , 2010, 97, 109-115.	2.9	78
142	Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. <i>Journal of Neuro-Oncology</i> , 2010, 97, 305-308.	2.9	27
143	Frequent MGMT (O6-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. <i>Radiology and Oncology</i> , 2010, 44, 113-20.	1.7	11
144	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology</i> , The, 2009, 10, 459-466.	10.7	6,451

#	ARTICLE	IF	CITATIONS
145	High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients.. Blood, 2009, 114, 2985-2985.	1.4	0
146	Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. Journal of Neuro-Oncology, 2008, 89, 211-218.	2.9	27
147	Meningioma. Critical Reviews in Oncology/Hematology, 2008, 67, 153-171.	4.4	301
148	Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. Brain Pathology, 2008, 18, 520-532.	4.1	189
149	A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 2008, 10, 1019-1024.	1.2	74
150	Venous thromboembolism and survival in patients with high-grade glioma. Neuro-Oncology, 2007, 9, 89-95.	1.2	119
151	[11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. Journal of Neuro-Oncology, 2007, 84, 305-314.	2.9	44
152	Reply to letter to the editor by Maddocks M. T. et al., "Neuromuscular electrical stimulation (NMES), a proactive supportive therapy or both?" regarding our publication "Neuromuscular electrical stimulation for a patient with metastatic lung cancer" a case report and recent experiences in glioblastoma patients. Supportive Care in Cancer, 2007, 15, 113-113.	2.2	1
153	Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study. Wiener Klinische Wochenschrift, 2006, 118, 230-238.	1.9	6
154	Neuromuscular electrical stimulation for a patient with metastatic lung cancer" a case report. Supportive Care in Cancer, 2006, 14, 970-973.	2.2	36
155	Chemotherapy for malignant gliomas. Wiener Medizinische Wochenschrift, 2006, 156, 346-350.	1.1	6
156	Gender aspects of treatment and drug related toxicity in medical oncology. Wiener Medizinische Wochenschrift, 2006, 156, 534-540.	1.1	10
157	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genetics and Cytogenetics, 2006, 166, 46-55.	1.0	22
158	Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anti-Cancer Drugs, 2005, 16, 1139-1143.	1.4	41
159	Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. Anti-Cancer Drugs, 2005, 16, 185-190.	1.4	4
160	No prognostic impact of survivin expression in glioblastoma. Acta Neuropathologica, 2005, 109, 534-538.	7.7	26
161	P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. Journal of Neuro-Oncology, 2005, 72, 255-260.	2.9	176
162	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB Journal, 2005, 19, 960-962.	0.5	56

#	ARTICLE	IF	CITATIONS
163	Seven Novel and Stable Translocations Associated with Oncogenic Gene Expression in Malignant Melanoma. <i>Neoplasia</i> , 2005, 7, 303-311.	5.3	52
164	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	27.0	17,395
165	Stabilization of a Progressive Hemangioblastoma under Treatment with Thalidomide. <i>Journal of Neuro-Oncology</i> , 2004, 66, 295-299.	2.9	22
166	Glioblastoma with Spinal Seeding. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 455-457.	2.0	18
167	Microvessel density is not crucial for scintigraphic visualization of brain tumors using 99mTc-MIBI. <i>Microvascular Research</i> , 2004, 67, 218-222.	2.5	6
168	Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences. <i>Anti-Cancer Drugs</i> , 2004, 15, 495-8.	1.4	4
169	Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. <i>Journal of Neuro-Oncology</i> , 2003, 63, 55-61.	2.9	53
170	Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 389-397.	1.9	13
171	Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2003, 146, 161-166.	1.0	15
172	Unexpected out-of-hospital deaths in persons aged 85 years or older: an autopsy study of 1886 patients. <i>American Journal of Medicine</i> , 2003, 114, 365-369.	1.5	16
173	Survival and prognostic factors of patients with unresectable glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2003, 14, 305-312.	1.4	42
174	Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2003, 14, 137-143.	1.4	13
175	Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2003, 14, 437-442.	1.4	30
176	Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes. <i>Brain Pathology</i> , 2003, 13, 133-143.	4.1	132
177	Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 294-298.	2.3	19
178	Prognostic relevance of p53 protein expression in glioblastoma. <i>Oncology Reports</i> , 2002, 9, 703-7.	2.6	23
179	Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. <i>Anti-Cancer Drugs</i> , 2001, 12, 209-212.	1.4	10
180	Karyotypic Findings in Two Cases of Male Breast Cancer. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 190-193.	1.0	16

#	ARTICLE	IF	CITATIONS
181	Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma. <i>Journal of Neuro-Oncology</i> , 2000, 49, 263-268.	2.9	14
182	Does 99mTc-Sestamibi in High-Grade Malignant Brain Tumors Reflect Blood-Brain Barrier Damage Only?. <i>NeuroImage</i> , 2000, 12, 109-111.	4.2	17
183	Cytogenetic Analysis and Fluorescence In Situ Hybridization in a Case of IgD Multiple Myeloma. <i>Cancer Genetics and Cytogenetics</i> , 1998, 105, 172-176.	1.0	3
184	Recurrent cardiac tamponade as first manifestation of gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 621-622.	1.6	2
185	Impaired hemorheology in patients with postmastectomy lymphedema. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 283-288.	2.5	3
186	Interferon-alfa-2b for meningioma. <i>Lancet</i> , The, 1995, 345, 331.	13.7	26
187	Double modulation of 5-fluorouracil by high-dose leucovorin and interferon-2b in advanced colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 314-318.	2.5	3
188	Tetrasomy 8 in acute monoblastic leukemia (AML-M5a) with myelosarcomatosis of the skin. <i>Cancer Genetics and Cytogenetics</i> , 1993, 71, 50-54.	1.0	31
189	Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. <i>Cancer Genetics and Cytogenetics</i> , 1992, 61, 14-25.	1.0	70
190	Translocation (16;21)(p11;q22) in acute monoblastic leukemia with erythrophagocytosis. <i>Cancer Genetics and Cytogenetics</i> , 1991, 54, 61-66.	1.0	16